These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32961814)

  • 1. A Direct Comparison between the Lateral Magnetophoretic Microseparator and AdnaTest for Isolating Prostate Circulating Tumor Cells.
    Cho H; Chung JS; Han KH
    Micromachines (Basel); 2020 Sep; 11(9):. PubMed ID: 32961814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest.
    Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC
    BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical evaluation for somatic mutation detection in circulating tumor cells isolated using a lateral magnetophoretic microseparator.
    Cho H; Kim J; Han SI; Han KH
    Biomed Microdevices; 2016 Oct; 18(5):91. PubMed ID: 27628059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
    Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
    Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer.
    Russo GI; Bier S; Hennenlotter J; Beger G; Pavlenco L; van de Flierdt J; Hauch S; Maas M; Walz S; Rausch S; Bedke J; Morgia G; Stenzl A; Todenhöfer T
    BJU Int; 2018 Jul; 122(1):152-159. PubMed ID: 29542849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor Cells Expressing the Prostate Specific Membrane Antigen (PSMA) Indicate Worse Outcome in Primary, Non-Metastatic Triple-Negative Breast Cancer.
    Kasimir-Bauer S; Keup C; Hoffmann O; Hauch S; Kimmig R; Bittner AK
    Front Oncol; 2020; 10():1658. PubMed ID: 33014830
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene Expression Analysis of Immunomagnetically Enriched Circulating Tumor Cell Fraction in Castration-Resistant Prostate Cancer.
    Škereňová M; Mikulová V; Čapoun O; Švec D; Kološtová K; Soukup V; Honová H; Hanuš T; Zima T
    Mol Diagn Ther; 2018 Jun; 22(3):381-390. PubMed ID: 29725990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective Circulating Tumor Cell Isolation Using Epithelial and Mesenchymal Markers in Prostate and Pancreatic Cancer Patients.
    Cha J; Cho H; Chung JS; Park JS; Han KH
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes.
    Nimir M; Ma Y; Jeffreys SA; Opperman T; Young F; Khan T; Ding P; Chua W; Balakrishnar B; Cooper A; De Souza P; Becker TM
    Cells; 2019 Jul; 8(7):. PubMed ID: 31288377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
    Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
    Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.
    Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M
    Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
    Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
    Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
    Danila DC; Samoila A; Patel C; Schreiber N; Herkal A; Anand A; Bastos D; Heller G; Fleisher M; Scher HI
    Cancer J; 2016; 22(5):315-320. PubMed ID: 27749322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer panel analysis of circulating tumor cells in patients with breast cancer.
    Lee CH; Lee SJ; Choi SH; Ahn SH; Son BH; Lee JW; Yu JH; Kwon NJ; Lee WC; Yang KS; Lee DH; Han DY; Choi MS; Park PS; Lee HK; Kim MS; Lee J; Jeon BH
    Oncol Lett; 2018 Jul; 16(1):612-618. PubMed ID: 29928447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.
    Čapoun O; Mikulová V; Jančíková M; Honová H; Kološtová K; Sobotka R; Michael P; Zima T; Hanuš T; Soukup V
    Anticancer Res; 2016 Apr; 36(4):2019-26. PubMed ID: 27069196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
    Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cell microseparator based on lateral magnetophoresis and immunomagnetic nanobeads.
    Kim S; Han SI; Park MJ; Jeon CW; Joo YD; Choi IH; Han KH
    Anal Chem; 2013 Mar; 85(5):2779-86. PubMed ID: 23384087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-stage microfluidic chip for selective isolation of circulating tumor cells (CTCs).
    Hyun KA; Lee TY; Lee SH; Jung HI
    Biosens Bioelectron; 2015 May; 67():86-92. PubMed ID: 25060749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Immune-Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood.
    Chelakkot C; Ryu J; Kim MY; Kim JS; Kim D; Hwang J; Park SH; Ko SB; Park JW; Jung MY; Kim RN; Song K; Kim YJ; Choi YL; Lee HS; Shin YK
    Micromachines (Basel); 2020 May; 11(6):. PubMed ID: 32486306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.